Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Catalent entering gene therapy market via Paragon buy

Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.

Read More »

Coeptis Pharma Buys Elto Pharma for Phase II Parkinson’s Asset

Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma, which is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.

Read More »

GSK seeks mid-September 2018 bids for $4 billion Indian Horlicks unit: sources

GlaxoSmithKline is seeking initial bids by mid-September for the company’s India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said.

Read More »

Shire’s Sales Up Ahead of Takeda Acquisition

As Shire’s acquisition by Takeda Pharmaceutical approaches, the global biotechnology company reported a solid second-quarter 2018.

Read More »

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

Read More »

Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U.S.

Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.

Read More »

A Behind-the-Scenes Look at Takeda Pharma’s Takeover of Shire

  By Mark Terry   The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal. Takeda originally planned to approach Shire’s board of directors about the acquisition on April 1, but published rumors […]

Read More »

Roche and Subsidiaries Ramp Up Treatment Options for Multiple Sclerosis

Roche and its subsidiaries are ramping up treatment options for multiple sclerosis. In April, the company acquired a regenerative therapy program for MS from Inception Sciences. Now, Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).

Read More »

Shire Rejects Takeda’s Acquisition Bid

According to Reuters UK, Japan’s Takeda Pharmaceutical made an official bid to acquire London’s Shire for about $60 billion, which was rejected.

Read More »

Veritas Capital to Acquire Revenue-Cycle, Ambulatory Care and Workforce Management Software Unit from GE Healthcare for $1 Billion

Veritas Capital, a leading private equity investment firm, and General Electric announced that an affiliate of Veritas entered into a definitive agreement with GE to acquire the Enterprise Financial Management (Revenue-Cycle, Centricity Business), Ambulatory Care Management (Centricity Practice Solution) and Workforce Management (formerly API Healthcare) assets comprising GE Healthcare’s Value-Based Care Division for $1.05 billion in cash.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom